Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label randomized multi-arm study of LXH254 combinations in previously treated BRAF V600- or NRAS-mutant unresectable or metastatic melanoma
MOH_2020-10-01_009307Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of naporafenib in melanoma and cutaneous melanoma (CM) (3 arms), sponsored by Novartis. Started Sep 2020; status: active, not recruiting.
02
Drugs
naporafenib
03
Conditions
melanomacutaneous melanoma (CM)
Beyond the preview
Go deeper on MOH_2020-10-01_009307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-01_009307.